340B Program Changes Could Shift Prescribing To Lower Cost Biosimilars

Hospitals often earn large spreads on high-volume branded drugs bought via 340B. Reforms may make hospitals more price-sensitive, raisin uptake of lower-cost biosimilars.

Raccontata daforbes.com